
|Videos|December 9, 2021
Dr. Moses summarizes SUO presentation on financial and toxicity considerations for patients with prostate cancer
Author(s)Urology Times staff
“We need to be aware of what patients are having to pay out of pocket, how it can impact their overall quality of life, [and] how can it impact their ability to pay for other necessities in life,” says Kelvin A. Moses, MD, PhD, FACS.
Advertisement
In this video, Kelvin A. Moses, MD, PhD, FACS, discusses the key points from his presentation, “Financial and toxicity considerations when managing advanced PCa,” which he made recently at the 2021 Society of Urologic Oncology Annual Meeting. Moses is an associate professor of urology and fellowship director of urologic oncology at the Vanderbilt University Medical Center in Nashville, Tennessee.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5













